Nadia Quignot
Overview
Explore the profile of Nadia Quignot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sibon I, Mohammedi K, Quignot N, Read S, Kapnang R, Khachatryan A, et al.
Eur Stroke J
. 2025 Feb;
:23969873251319172.
PMID: 39950831
Introduction: Contemporary estimates of the impact of type 2 diabetes (T2D) on stroke outcomes are important for care planning and resource allocation. This retrospective cohort study compared the incidence of...
2.
Mahe I, Gusto G, Quignot N, Khachatryan A, Chaves J, Moniot A, et al.
Res Pract Thromb Haemost
. 2025 Jan;
9(1):102642.
PMID: 39868402
Background: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event....
3.
Lip G, Benamouzig R, Martin A, Pesce G, Gusto G, Quignot N, et al.
PLoS One
. 2025 Jan;
20(1):e0317895.
PMID: 39841678
Background: Risk factors and comorbidities can complicate management of non-valvular atrial fibrillation. We describe and compare real-world safety and effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and vitamin...
4.
Lip G, Benamouzig R, Martin A, Pesce G, Gusto G, Quignot N, et al.
PLoS One
. 2024 Nov;
19(11):e0310322.
PMID: 39546473
Background: This observational study compared effectiveness and safety of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) or vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) at high...
5.
Baldwin J, Udeze C, Li N, Boulmerka L, Dahal L, Pesce G, et al.
Curr Med Res Opin
. 2024 Oct;
40(12):2117-2124.
PMID: 39466333
Objective: This retrospective, real-world claims database analysis described the clinical burden and healthcare resource utilization (HCRU) among patients with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) in France....
6.
Hulin C, Quignot N, Jiang H, Mechiche H, Desamericq G
EJHaem
. 2024 Aug;
5(4):887-891.
PMID: 39157605
No abstract available.
7.
Baldwin J, Udeze C, Li N, Boulmerka L, Dahal L, Pesce G, et al.
Curr Med Res Opin
. 2024 Jun;
40(8):1289-1295.
PMID: 38873781
Objective: To describe the clinical burden and healthcare resource utilization associated with managing transfusion-dependent β-thalassemia (TDT) in France. Methods: We used the French National Health Data System (système national des...
8.
Mohammedi K, Fauchier L, Quignot N, Khachatryan A, Banon T, Kapnang R, et al.
Cardiovasc Diabetol
. 2024 May;
23(1):183.
PMID: 38812009
Background: People with type 2 diabetes (T2D) are at elevated risk of cardiovascular disease (CVD) including stroke, yet existing real-world evidence (RWE) on the clinical and economic burden of stroke...
9.
Read S, Quignot N, Kapso-Kapnang R, Comerford E, Zheng Y, Gainford C, et al.
Breast Cancer Res Treat
. 2024 Jan;
204(3):579-588.
PMID: 38206533
Purpose: To assess real-world treatment patterns in patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) who received cyclin-dependent kinase...
10.
Holtick U, Quignot N, Kapso-Kapnang R, Reichenbach D, Kelly M, Burrell A, et al.
Transplant Proc
. 2024 Jan;
56(1):191-200.
PMID: 38199852
Background: Acute graft-vs-host disease (aGVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), yet there are limited data on the clinical and economic burden of aGVHD in...